Alterity Therapeutics Limited | PRAN




Peers Price Chg Day Year Date
Arca Biopharma 59.66 -0.96 -1.58% 421.46% May/26
Brainstorm Cell Therapeutics 0.62 -0.06 -8.84% -42.59% May/26
Bio Path 0.03 -0.01 -15.41% -85.98% May/21
Capricor Therapeutics 29.08 0.21 0.73% 177.48% May/26
Cara Therapeutics 3.50 -0.08 -2.10% -89.53% May/26
CSL 96.90 -1.57 -1.59% -61.08% May/26
Esperion Therapeutics 3.13 0 0% 281.75% May/26
Insmed 108.16 1.92 1.81% 59.01% May/26
aTyr Pharma 0.50 0.01 1.29% -87.18% May/26
Minerva Neurosciences 5.13 -0.13 -2.47% 244.30% May/26

Indexes Price Day Year Date
USND 26569 225.36 0.86% 38.39% May/26

Alterity Therapeutics Limited traded at $4.14 this Friday May 22nd, decreasing $0.04 or 0.96 percent since the previous trading session. Looking back, over the last four weeks, Alterity Therapeutics Limited lost 19.61 percent. Over the last 12 months, its price fell by 1.43 percent. Looking ahead, we forecast Alterity Therapeutics Limited to be priced at 4.19 by the end of this quarter and at 3.96 in one year, according to Trading Economics global macro models projections and analysts expectations.

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company focuses on developing disease modifying treatments for neurodegenerative conditions. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The Company also has a drug discovery platform generating chemical to intercede in disease processes.